Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

@article{SanMiguel2014PanobinostatPB,
  title={Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.},
  author={Jes{\'u}s F San-Miguel and V{\^a}nia Tietsche de Moraes Hungria and Sung Soo Yoon and Meral Beksac and Meletios Athanasios Dimopoulos and Ashraf Elghandour and Wieslaw Wiktor Jędrzejczak and Andreas G{\"u}nther and Thanyaphong Na Nakorn and Noppadol Siritanaratkul and P. Poggi – Corradini and Suporn Chuncharunee and Je-Jung Lee and Robert L. Schlossman and Tatiana Vladimirovna Shelekhova and Kwee L. Yong and Daryl Chen Lung Tan and Tontanai Numbenjapon and Jamie D. Cavenagh and Jian Hou and Richard Leblanc and Hareth Nahi and Lugui Qiu and Hans J{\"u}rgen Salwender and Stefano Pulini and Philippe Moreau and Krzysztof Warzocha and Darrell J White and Joan Blad{\'e} and Wenming Chen and Javier de la Rubia and Peter Gimsing and Sagar Lonial and Jonathan L. Kaufman and Enrique Mar{\'i}a Ocio and Ljupco Veskovski and Sang Kyun Sohn and Ming-chung Wang and Jae Hoon Lee and Hermann Einsele and Monika Sopala and Claudia Silvia Corrado and B Bengoudifa and Florence Binlich and Paul G Richardson},
  journal={The Lancet. Oncology},
  year={2014},
  volume={15 11},
  pages={1195-206}
}
BACKGROUND Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma activity when combined with bortezomib and dexamethasone. We aimed to compare panobinostat, bortezomib, and dexamethasone with placebo, bortezomib, and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma. METHODS PANORAMA1 is a multicentre, randomised, placebo-controlled, double-blind phase 3 trial of patients with relapsed or relapsed and… CONTINUE READING